MILPITAS, Calif., November 07, 2022 – Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, today announced its Bigfoot Unity® Diabetes Management System is now compatible with four additional rapid-acting insulin products, including two unbranded biologics. All four insulin products are offered at a reduced price without compromising quality, helping to expand insulin access for people with diabetes.
Data Were Presented at the American Diabetes Association 82nd Scientific Sessions
MILPITAS, Calif., June 5, 2022 – Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, presented real-world data from its late-breaking abstract presented at the American Diabetes Association 82nd Annual Scientific Sessions. Data from the real-world retrospective analysis suggests that, for people on multiple daily injections (MDI) of insulin, using the Bigfoot Unity System has the potential for rapid and durable improvement in glycemic control.
Milpitas, Calif., June 1, 2022 – Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, today announced late-breaking presentation of “The First Real World Experience with Bigfoot Unity: A 3-Month Retrospective Analysis” at the 2022 American Diabetes Association (ADA) 82nd Scientific Sessions.
Milpitas, CA, May 26, 2022 - Bigfoot Biomedical, announced today Healthcare commercialization veteran Matt Rainville will lead commercial strategies. In this role, Rainville will lead the growth of the fully commercial Bigfoot Unity® Diabetes Management Program as Bigfoot expands access to diabetes clinics and health systems in 2022 and beyond.
Milpitas, CA, December 16, 2021 - With its Bigfoot Unity™ Diabetes Management Program fully commercial, Bigfoot looks to broaden access to diabetes centers, endocrinology practices and health systems in 2022, as well as expand its development pipeline.
Milpitas, CA, December 1, 2021 - Since launching in late summer 2021, the innovative Bigfoot UnityTM Diabetes Management Program and its Bigfoot Clinic HubTM are demonstrating that technology can help transform how health care professionals (HCPs) manage their patient populations on multiple daily injections (MDI) of insulin.
Milpitas, CA, June 24, 2021 –Bigfoot Biomedical announced today that its innovative Bigfoot Unity™ Diabetes Management Program is now available to diabetes clinics and endocrinology practices in select markets across the U.S.
Milpitas, CA, June 15, 2021 –Bigfoot Biomedical announced today that it has acquired the intellectual property assets of Common Sensing, a Cambridge, MA-based company that develops and manufactures data-driven hardware and software solutions for people using injectable medicine, including Gocap.
Milpitas, CA, May 10, 2021 – Bigfoot Biomedical announced today that the FDA has granted 510(k) clearance for first-of-its-kind Bigfoot Unity™ Diabetes Management System, which features connected smart pen caps that recommend insulin doses for people using multiple daily injection (MDI) therapy.
Milpitas, CA, March 17, 2021 – Bigfoot Biomedical announced today that it has secured new financing of up to $57 million from Madryn Asset Management LP
Milpitas, CA, December 9, 2020 – As it readies for FDA clearance of its first product and subsequent launch of its innovative program, Bigfoot Biomedical announced today it has established an experienced commercial team led by senior vice president Berkley Nelson.
Milpitas, CA, June 12, 2020 – Bigfoot Biomedical, Inc. announced today the appointment of Dr. Jim Malone as Chief Medical Officer. Dr. Malone, an endocrinologist specializing in diabetes, spent 12 years in clinical practice and 21 years in clinical research, where he developed diabetes products and delivery devices at Eli Lilly & Company.
Milpitas, CA, June 2, 2020- Bigfoot Biomedical® Closes Series C Financing with $55 Million as Company Readies for FDA Submission of Bigfoot Unity. Funding to Support its Breakthrough Therapy and Telemedicine Solutions for People Living with Insulin-Requiring Type 1 and Type 2 Diabetes
Milpitas, CA, March 13, 2020 – Bigfoot Biomedical, Inc. announced today key promotions and new reporting structures as the company readies for regulatory submission and commercial launch of Bigfoot Unity™ Diabetes Management Program.
Milpitas, CA, United States, and London, England, June 8, 2017 – Bigfoot Biomedical, Inc., a new kind of medical device company harnessing the power of machine learning to automatically and continuously optimize insulin delivery for people with insulin-requiring diabetes, today announced that it has acquired London-based biotech company Patients Pending, LTD, makers of the Timesulin® insulin pen timer cap, and its Bluetooth-enabled insulin pen dose capture technology.
Milpitas, CA, and Pittsburgh, PA – August 1, 2019 – Bigfoot Biomedical, Inc., and Allegheny Health Network (AHN) – a Highmark Health company – announced today a collaboration to further advance Bigfoot Biomedical’s first-in-kind data-driven solutions for optimizing the dosing and delivery of insulin for people with diabetes.
Milpitas, CA, Indianapolis, IN. – January 7, 2019 – Bigfoot Biomedical, Inc., a diabetes company using artificial intelligence to develop solutions for optimizing the dosing and delivery of insulin, today announced a non-exclusive cooperation agreement with Eli Lilly and Company (NYSE: LLY) to support integration of Lilly’s insulin products into Bigfoot’s systems currently in development.
Milpitas, California, May 10, 2018 – Bigfoot Biomedical, Inc., a diabetes solutions company using artificial intelligence to optimize the dosing and delivery of insulin for people with insulin-requiring diabetes, has been included as part of a demonstration showcasing new Android security features at the annual Google I/O developer conference in Mountain View, California.
Milpitas, California, March 28, 2018 – Bigfoot Biomedical, Inc., a diabetes solutions company harnessing the power of artificial intelligence to optimize the dosing and delivery of insulin for people with insulin-requiring diabetes, today announced that the company has completed a $55 million Series B equity financing with new investments from Abbott and other new and existing investors, bringing the total amount of equity raised by the company to over $90 million.
Milpitas, California, December 18, 2017 – Bigfoot Biomedical, Inc. today announced that the company has raised $37 million in the initial tranche of a Series B equity financing. The round is co-led by funds managed by a new investor, Janus Henderson Investors, along with Bigfoot’s largest existing investor, Quadrant Capital Advisors, Inc.
Milpitas, California, November 3, 2017 – Bigfoot Biomedical, Inc., a medical device company harnessing the power of artificial intelligence to automatically and continuously optimize insulin delivery for people with insulin-requiring diabetes, will present data from a clinical trial at the 17th Annual Diabetes Technology Meeting in Bethesda, Maryland.
Milpitas, California, United States, and Burgdorf, Switzerland, October 24, 2017 – Bigfoot Biomedical and Ypsomed (SWX:YPSN) today announced that the companies have entered into an agreement under which Ypsomed will supply Bigfoot with a customized proprietary version of its Orbit® infusion sets as part of Bigfoot’s investigational automated insulin pump-based solution for use in a pivotal trial.
Abbott Park, Ill., and Milpitas, Calif., July 13, 2017 – Abbott and Bigfoot Biomedical today announced that the companies have entered into an agreement to develop and commercialize diabetes management systems, integrating Abbott's FreeStyle® Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the United States.
Milpitas, CA, May 24, 2017 – Bigfoot Biomedical, Inc., a new kind of medical device company harnessing the power of machine learning to automatically and continuously optimize insulin delivery for people with insulin-requiring diabetes, today announced that biomedical industry entrepreneur Karen Talmadge, PhD, has joined its experienced Board of Directors.
Milpitas, CA, May 18, 2017 – Bigfoot Biomedical, Inc., a privately held innovative machine learning company focused on developing solutions intended for people with insulin-requiring diabetes, today announced the members of its Clinical Advisory Board which will provide expert guidance to the team at Bigfoot working to develop an innovative product portfolio.
Milpitas, CA, February 17, 2017 – Bigfoot Biomedical, Inc. today announced a significant investment from T1D Exchange, a nonprofit organization driving faster, more informed research and commercialization efforts to improve outcomes for people with T1D. The collaboration with Bigfoot marks the first investment out of T1D Exchange’s multi-million dollar initiative to accelerate the development and delivery of automated insulin delivery technology and solutions.
Milpitas, CA, January 27, 2017 – Bigfoot Biomedical, Inc., a highly anticipated machine learning company founded by people directly impacted by Type 1 Diabetes (T1D), today announced an equity investment from the newly established JDRF T1D Fund, a strategic venture philanthropy fund with a focus on making high‐impact, early‐stage investments to accelerate commercial development of life‐changing therapies for people living with T1D.
Milpitas, CA, October 19, 2016 – Bigfoot Biomedical, Inc., a highly anticipated precision medicine company founded by people directly impacted by Type 1 Diabetes (T1D) today announced a Series A investment of $35.5 million, led by entities advised by Quadrant Capital Advisors, with participation from Cormorant Asset Management, Senvest Capital, and Visionnaire Ventures. The funding will support final development activities for Bigfoot’s smartloop™ automated insulin delivery service, the world’s first Internet-of-Things medical device system delivered as a monthly service.
Milpitas, CA, July 21, 2016 – Bigfoot Biomedical, Inc., a company founded and led by people affected by and living with Type 1 Diabetes (T1D), has enrolled its first patients in a clinical trial for the Bigfoot smartloop™ automated insulin delivery system.
New York, NY — Bigfoot Biomedical, Inc. today announced it has entered into a development agreement with Dexcom, Inc. to integrate data from the Dexcom Continuous Glucose Monitoring (CGM) System into the Bigfoot insulin delivery system. Bigfoot Biomedical is developing a comprehensive Type 1 Diabetes (T1D) Management System employing simple design, cloud connectivity, and human-centered-automation. The newly announced partnership will enable glucose data to travel seamlessly from the Dexcom transmitter into the Bigfoot system to enable automated delivery of insulin for people with T1D.
New York, NY, May 28, 2015 – Bigfoot Biomedical, Inc., a company developing a comprehensive Type 1 Diabetes (T1D) Management System employing simple design, cloud connectivity, and human-centered-automation, today announced it has acquired all assets of Asante Solutions, manufacturer of the Asante Snap insulin pump. The acquisition marks a strategically meaningful step towards Bigfoot’s broader vision to provide all people with T1D an accessible, affordable, automated, connected solution.